IBM Retirement Fund bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,362 shares of the company’s stock, valued at approximately $213,000.
Other institutional investors have also recently bought and sold shares of the company. Zions Bancorporation bought a new position in IDEXX Laboratories in the third quarter valued at about $162,000. Benjamin F. Edwards & Company Inc. raised its position in IDEXX Laboratories by 1,000.0% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after purchasing an additional 1,000 shares during the last quarter. SignalPoint Asset Management LLC bought a new position in IDEXX Laboratories in the fourth quarter valued at about $200,000. Ledyard National Bank raised its position in shares of IDEXX Laboratories by 58.9% during the fourth quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock worth $203,000 after acquiring an additional 480 shares during the last quarter. Finally, BB&T Securities LLC bought a new position in shares of IDEXX Laboratories during the third quarter worth about $213,000. Hedge funds and other institutional investors own 86.02% of the company’s stock.
Shares of IDEXX Laboratories, Inc. (IDXX) traded up $1.03 during mid-day trading on Tuesday, reaching $182.48. The company’s stock had a trading volume of 427,600 shares, compared to its average volume of 608,256. The company has a market capitalization of $15,898.17, a P/E ratio of 62.07, a P/E/G ratio of 2.24 and a beta of 0.58. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97. IDEXX Laboratories, Inc. has a 1-year low of $141.02 and a 1-year high of $198.73.
IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million during the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.58 earnings per share. research analysts predict that IDEXX Laboratories, Inc. will post 4.09 EPS for the current year.
In other IDEXX Laboratories news, VP Brian P. Mckeon sold 6,602 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $181.36, for a total value of $1,197,338.72. Following the completion of the sale, the vice president now owns 47,040 shares of the company’s stock, valued at $8,531,174.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Giovani Twigge sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 86,762 shares of company stock valued at $15,202,484. 2.77% of the stock is currently owned by corporate insiders.
A number of brokerages have recently issued reports on IDXX. Canaccord Genuity restated a “buy” rating and set a $210.00 price objective on shares of IDEXX Laboratories in a research report on Monday, January 29th. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 9th. Piper Jaffray Companies raised their price objective on IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 price objective for the company in a research report on Monday, February 5th. Finally, Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $194.00.
TRADEMARK VIOLATION WARNING: This piece of content was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/02/20/ibm-retirement-fund-takes-213000-position-in-idexx-laboratories-inc-idxx.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.